The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! About 7.97 million shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 67.26% since March 11, 2016 and is downtrending. It has underperformed by 72.72% the S&P500.
The move comes after 6 months negative chart setup for the $7.66B company. It was reported on Oct, 14 by Barchart.com. We have $20.55 PT which if reached, will make NYSE:VRX worth $612.80 million less.
Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on October, 17. They expect $1.80 earnings per share, down 33.33% or $0.90 from last year’s $2.7 per share. VRX’s profit will be $616.66 million for 3.10 P/E if the $1.80 EPS becomes a reality. After $1.40 actual earnings per share reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts 28.57% EPS growth.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 74 analyst reports since July 21, 2015 according to StockzIntelligence Inc. On Tuesday, September 29 the stock rating was initiated by Nomura with “Buy”. The rating was downgraded by Mizuho to “Neutral” on Thursday, December 17. Canaccord Genuity maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, March 16. Canaccord Genuity has “Hold” rating and $40 price target. The firm earned “Neutral” rating on Tuesday, March 8 by Mizuho. Stifel Nicolaus maintained the shares of VRX in a report on Wednesday, June 8 with “Buy” rating. The company was downgraded on Thursday, October 22 by BMO Capital Markets. Morgan Stanley maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, March 16 with “Equal-Weight” rating. The company was reinitiated on Monday, November 30 by IBC. The rating was initiated by BMO Capital Markets with “Market Perform” on Wednesday, June 29. The firm has “Buy” rating by Rodman & Renshaw given on Monday, April 11.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.06, from 0.92 in 2016Q1. The ratio fall, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Moreover, Canada Pension Plan Inv Board has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 45,510 shares. Citadel Advisors Ltd Co accumulated 0.03% or 1.43M shares. First New York Secs Limited Liability Ny accumulated 5,100 shares or 0% of the stock. Aqr Cap Mngmt holds 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 415,176 shares. Ig Mgmt Limited accumulated 418,330 shares or 0.03% of the stock. The New York-based Tiaa Cref Inv Limited Liability Co has invested 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Oppenheimer accumulated 19,651 shares or 0.01% of the stock. Winfield Associate Incorporated holds 75 shares or 0% of its portfolio. Prescott Group Cap Limited Com has 65,000 shares for 0.32% of their US portfolio. Seven Eight Cap Ltd Company has invested 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Pcj Inv Counsel Ltd accumulated 0.01% or 10,000 shares. Comerica Savings Bank accumulated 18,599 shares or 0% of the stock. Moreover, Alps Advsr has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 10,233 shares. Magnetar Ltd Limited Liability Company accumulated 13,211 shares or 0% of the stock. Spot Trading Lc accumulated 0.02% or 56,937 shares.
Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 insider sales for $5.04 million net activity. KARABELAS ARGERIS N had bought 4,000 shares worth $98,600. $4.94M worth of shares were bought by PAPA JOSEPH C on Thursday, June 9.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Prnewswire.com which released: “Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action …” on October 14, 2016, also Fool.com with their article: “These 2 Factors Pushed Valeant Pharmaceuticals Intl. Inc. Down 15% in September” published on October 07, 2016, Seekingalpha.com published: “Valeant Pharmaceuticals: More Downside Ahead, Avoid” on October 13, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc” published on September 30, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock to Regain Value?” with publication date: September 27, 2016.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.